Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 16/20 | 1.00 |
| ▸ | DRD2 | P14416 | 15/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14502883 | 1.00 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2ASIGMAR1 | |
| SCHEMBL8797434 | 1.00 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2ASIGMAR1 | |
| SCHEMBL6844226 | 1.00 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2ASIGMAR1 | |
| SCHEMBL5408639 | 1.00 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2ASIGMAR1 | |
| SCHEMBL5415647 | 1.00 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2ASIGMAR1 | |
| SCHEMBL7098507 | 1.00 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2ASIGMAR1 | |
| SCHEMBL14532740 | 1.00 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2ASIGMAR1 | |
| SCHEMBL7558449 | 0.93 | DRD4 (0.88) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL6905943 | 0.93 | DRD4 (0.88) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL6843875 | 0.92 | DRD4 (0.86) | DRD4DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2004-03-11 | — | — | US | claimed |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2002-07-18 | — | — | US | claimed |
| EP-1213031-A2 | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | Pfizer Products Inc. (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | claimed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| EP-0783503-B1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[ 1,2-A]PYRAZINE DERIVATIVES | PFIZER (US) | 2001-11-28 | — | — | EP | claimed |
| US-5852031-A | 2,7-substituted octahydro-1H-pyrido 1,2-a!pyrazine derivatives | PFIZER INC. (US) | 1998-12-22 | — | — | US | claimed |
| EP-0783503-A1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO 1,2-a]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1997-07-16 | — | — | EP | claimed |
| WO-1996010571-A1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[1,2-a]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1996-04-11 | — | — | WO | claimed |
| US-7220753-B2 | 2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors | PFIZER INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20040214830-A1 | 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors | DESAI KISHOR A | 2004-10-28 | — | — | US | disclosed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| US-6231833-B1 | ADMINISTERING TO THE MAMMAL FOR TREATING SEROTONIN SYSTEM RELATED DISORDERS AN EFFECTIVE AMOUNT OF 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO(1,2-A)PYRAZINE DERIVATIVE AS LIGANDS FOR SEROTONIN RECEPTOR | PFIZER INC | 2001-05-15 | — | — | US | disclosed |
| EP-1074257-A1 | 2,7-Substituted octahydro-1H-pyrido (1,2-A)pyrazine derivatives as ligands for serotonin receptors | Pfizer Products Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| US-5852031-A | 2,7-substituted octahydro-1H-pyrido 1,2-a!pyrazine derivatives | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0788498-A1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0783503-A1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO 1,2-a]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010571-A1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[1,2-a]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | DRD4 4/4885DRD2 6/4885HTR1A 12/4885 |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | DRD4 31/4885DRD2 35/4885HTR1A 155/4885 |
| US-20040214830-A1 | 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors | HTR2C, HTR1A, HTR3A | DRD4 65/4885DRD2 27/4885HTR1A 2/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD4 2/4885DRD2 3/4885HTR1A 85/4885 |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | DRD4 4/4885DRD2 6/4885HTR1A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.